Trial Profile

Effect of PDE5 Inhibitor on Respiratory Symptoms in COPD Complicated by Pulmonary Hypertension

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tadalafil (Primary)
Indications Chronic obstructive pulmonary disease; Dyspnoea; Pulmonary hypertension
Focus Therapeutic Use
Acronyms BETTER COPD-PH

Most Recent Events

27 Jun 2024 Status changed from not yet recruiting to recruiting.
12 Feb 2024 Planned initiation date changed from 15 Jan 2024 to 1 Apr 2024.
05 Dec 2023 Planned initiation date changed from 18 Oct 2023 to 15 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com